Petros Grivas, MD, PhD, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, talks on the impact of PD-L1 expression on conventional urothelial bladder carcinoma genomic alteration profile. PD-L1 high and PD-L1 negative subtypes of urothelial bladder carcinoma differ in their genomic profiles, with PD-L1 negative tumors featuring greater frequencies of potentially targetable genomic alterations. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.